Ciforadenant
- Generic Name
- Ciforadenant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N7O3
- CAS Number
- 1202402-40-1
- Unique Ingredient Identifier
- 8KFO2187CP
- Background
Ciforadenant is under investigation in clinical trial NCT02253745 (Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)).
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05501054
- Locations
- ๐บ๐ธ
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธM D Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธDuke Cancer Institute, Durham, North Carolina, United States
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04280328
- Locations
- ๐บ๐ธ
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT02655822
- Locations
- ๐จ๐ฆ
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
๐บ๐ธMedical College of Wisconsin, Milwaukee, Wisconsin, United States
๐จ๐ฆCross Cancer Institute, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.